The deal came together in May 2018, with Takeda's final official bid coming in at around $62.2 billion. Takeda made five public bids for the company. The deal came in at about $30.33 per share in cash and 0.839 shares of Takeda stock. Currency fluctuations and Takeda's share price drop brought the value down to about $58 billion. Takeda is gaining both Shire's portfolio, heavy on rare disease drugs, and a stronger U.S. market presence. It's also picking up a significant amount of debt, which pushes the deal closer to a total of $80 billion. And it is largely this debt that caused some problems leading up to today's approval. As part of the final deal, Takeda has secured $30.9 billion in bank loans. A fairly small but vocal opposition group of Takeda shareholders calling itself "Think About Takeda's Bright Future" or TTBF, made several attempts to scuttle the deal. At the June annual meeting, the group, which at the time had about 130 shareholders in it, expressed their opposition and advanced a proposal that would require advance shareholder approval be required for large acquisitions. The proposal, however, only received about 10 percent of votes in favor, failing to pick up wider opposition support. And in September, the group gained a high-profile supporter, Kazu Takeda, a member of the Takeda family. He told  The Times, "Hasty decisions on big deals should be avoided.